BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Want to see TSE:BCT full AI Analyst Report?
BCT Stock Chart & Stats
C$10.64
-C$0.02(-3.08%)
At close: 4:00 PM EST
C$10.64
-C$0.02(-3.08%)
Day’s Range― - ―
52-Week RangeC$4.13 - C$51.50
Previous CloseN/A
Volume105.15K
Average Volume (3M)3.11K
Market Cap
C$29.94M
Enterprise Value-C$24.00M
Total Cash (Recent Filing)C$29.65M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.56
Shares Outstanding7,250,487
10 Day Avg. Volume3,860
30 Day Avg. Volume3,110
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Immunotherapy PipelineBriaCell's core strategy centers on a specialized, clinical-stage immunotherapy pipeline (Bria-IMT plus related cell/immune approaches) targeting breast cancer. A focused platform can create durable competitive advantages, enabling deep expertise, targeted partnerships, and clearer clinical development priorities over months to years.
Minimal-to-zero DebtA near-zero debt profile materially reduces solvency and interest-rate risks for a pre-commercial biotech. With little or no scheduled interest or principal obligations, management has more flexibility to prioritize R&D spending and structure financing rounds, improving long-term survivability through multi-quarter clinical programs.
Repaired Equity BaseTransitioning from negative to positive equity indicates successful capital injections or balance-sheet repair. That improvement enhances credibility with investors and counterparties, expands financing optionality for future trials, and reduces immediate solvency concerns—structural benefits that matter across multiple upcoming funding cycles.
Bears Say
No Revenue / Negative Gross ProfitAs a development-stage biotech, BriaCell lacks product revenue and reports negative gross profit, meaning it has no internal, recurring cash generation. Without commercialized products, long-term value depends on clinical outcomes or deals, increasing binary risk and making operational continuity contingent on external funding.
Widening Net LossesMaterially larger net losses (TTM ~45.8M) reflect intensified R&D and operating spending as programs advance. Persistently widening losses pressure cash reserves and increase reliance on financing, raising dilution and execution risk over the medium term if clinical or partnership progress does not accelerate value realization.
High Cash Burn And Funding RiskSustained negative operating and free cash flow (TTM ~-37M) shows losses translate directly into cash burn, limiting runway. This elevates refinancing and dilution risk, forcing frequent capital raises or partnerships to sustain trials. Such funding dependency is a durable constraint on strategy execution and shareholder outcomes.
BriaCell Therapeutics News
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$4.13 and its highest was C$51.50 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$29.94M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 17, 2026 which is in 29 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 10, 2026. The company reported -C$3.575 earnings per share for the quarter, missing the consensus estimate of N/A by -C$3.575.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Overvalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp does not currently pay dividends.
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 7,250,487 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$3.575 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.914%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
Microbix Biosystms
―
Resverlogix
―
Devonian Health Group
―
Thiogenesis Therapeutics Corp
―
Options Prices
Currently, No data available
---